Recent Articles in COVID-19

Shanghai Ascentage Pharma reported that olverembatinib effectively inhibited cytokine release storm in a preclinical test of the SARS-CoV-2 omicron variant. The study was conducted by researchers from Fred Hutchinson Cancer Research Center in Seattle. Olverembatinib is already approved in China for two forms of chronic myeloid leukemia. Although most COVID-19 patients develop only mild to moderate symptoms, 15-20% of them face the hyper-inflammation induced by a cytokine storm, which leads to respiratory failure. Ascentage said it anticipates follow-up studies of olverembatinib in patients with severe cases of COVID-19. More details....

Stock Symbols: (HK: 6855)

Share this with colleagues:  

RVAC Medicines, a Singapore mRNA platform company, completed a Series B funding led by CBC Group that brings total funds raised since its inception to $140 million. CBC also incubated the company. RVAC is headquartered in Singapore with R&D centers in Boston and Shanghai. The company will target unmet medical needs, especially in emerging markets, by developing novel vaccines and therapeutics including a potentially best-in-class COVID vaccine. It will use the proceeds to develop its pipeline and to build a new R&D center in Singapore and manufacturing facilities in Singapore and China

Share this with colleagues:  

Hangzhou Ascletis Pharma reported that its oral small molecule 3CLpro inhibitor was a more effective treatment for COVID-19 in preclinical tests than rival candidates. ASC11 is a company-developed 3-chymotrypsin like protease (3CLpro) inhibitor, which Ascletis believes has the potential to be a best-in-class antiviral treatment for COVID-19. The company expects to file an IND in China for the therapy in the second half of 2022 and to complete a Phase I trial in healthy adults by the end of 2022. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues:  

Shanghai Everest Medicines signed a memorandum of understanding with China Resources Pharmaceutical Group to form a partnered mRNA company. In September 2021, Everest announced a $500 million deal with Providence Pharma, a Canadian mRNA company, to develop Providence’s mRNA products in China including a clinical stage mRNA COVID-19 vaccine. The new mRNA partnership with CR Pharma will be built on Everest’s Providence-based portfolio, which includes several COVID vaccines and mRNA oncology candidates. Everest, which will be the controlling shareholder of the mRNA Co., did not disclose financial details. More details....

Stock Symbols: (HK 1952) (HK: 3320)

Share this with colleagues: